Research Papers:

FNDC3B promotes cell migration and tumor metastasis in hepatocellular carcinoma

Chin-Hui Lin, Yao-Wen Lin, Ying-Chun Chen, Chen-Chung Liao, Yuh-Shan Jou, Ming-Ta Hsu and Chian-Feng Chen _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:49498-49508. https://doi.org/10.18632/oncotarget.10374

Metrics: PDF 2086 views  |   HTML 3011 views  |   ?  


Chin-Hui Lin1, Yao-Wen Lin1, Ying-Chun Chen1, Chen-Chung Liao2, Yuh-Shan Jou3, Ming-Ta Hsu1, Chian-Feng Chen1

1VYM Genome Research Center, National Yang-Ming University, Taipei, Taiwan

2Proteomics Research Center, National Yang-Ming University, Taipei, Taiwan

3Institutes of Biomedical Sciences, Academia Sinica, Taipei, Taiwan

Correspondence to:

Chian-Feng Chen, email: [email protected]

Keywords: FNDC3B, hepatocellular carcinoma, metastasis

Received: April 05, 2016     Accepted: June 13, 2016     Published: July 01, 2016


Recurrence and metastasis are common in hepatocellular carcinoma (HCC) and correlate with poor prognosis. We investigated the role of fibronectin type III domain containing 3B (FNDC3B) in HCC metastasis. Overexpression of FNDC3B in HCC cell lines enhanced cell migration and invasion. On the other hand, knockdown of FNDC3B using short-hairpin RNA reduced tumor nodule formation in both intra- and extra-hepatic metastasis. High levels of FNDC3B were observed in metastatic HCCs and correlated with poor patient survival and shorter recurrence time. Mutagenesis and LC-MS/MS analyses showed that FNDC3B promotes cell migration by cooperating with annexin A2 (ANXA2). Furthermore, FNDC3B and ANXA2 expression correlated negatively with patient survival. Our results indicate that FNDC3B behaves like an oncogene by promoting cell migration. This suggests FNDC3B could serve as a biomarker and therapeutic target for HCC metastasis.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10374